Basecamp Research appoints Brands2Life to build global awareness of its breakthrough AI therapeutics models

London, 08 April, 2026: Brands2Life has been appointed by Basecamp Research, one of the world’s hottest global AI biology companies, to help power its growth through an ambitious global communications programme, following a competitive pitch process.

Basecamp Research combines ethically sourced biological data from around the world with cutting-edge machine learning and AI models to unlock new insights into disease biology and drug discovery. As the business continues to scale its scientific and commercial ambition, it sought an agency with a deep understanding of both life sciences and AI, to help build multiple, compelling angles for global media.

Brands2Life is now working with Basecamp Research on earned media, thought leadership, events and senior profiling. It is focusing on helping the company articulate the full breadth of its proposition, spanning its advanced EDEN AI models, the Trillion Gene Atlas biological data initiative, gene editing and therapeutic development, to global audiences across life sciences, technology, investment and business media. The agency is also acting as a strategic advisor at key business moments, including financial milestones, partnerships and major scientific breakthroughs.

D’Arcy Doran, Head of Communications and Marketing at Basecamp Research, said: “We selected Brands2Life for its deep global media relationships, strong understanding of AI and life sciences, and the team’s ability to develop multiple angles and storylines that support our commercial, scientific and corporate objectives. We’ve already got off to a flying start with dedicated stories on BBC Radio 4, Sky News, the Financial Times and Bloomberg, and we’re excited to see what’s next.”

Kate Smith, Deputy Managing Director at Brands2Life and life sciences lead, said: “Basecamp Research is a brilliant example of an organisation transforming our world, using AI to fundamentally change how we understand biology and how new medicines are developed. With the scale of its ambition and the therapeutic breakthroughs it is driving, it deserves a huge amount of spotlight, so we’re excited to help continue evolving its narrative and secure the depth of coverage that reflects the impact of its work.”